Related Experiment Video
Updated: Jul 11, 2026
09:38
Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Apolipoprotein E polymorphism--a risk factor for metabolic syndrome
Anca Sima1, Alexandru Iordan, Camelia Stancu
1Department of Lipoproteins and Atherosclerosis, Institute of Cellular Biology and Pathology Nicolae Simionescu, Bucharest, Romania. anca.sima@icbp.ro
Clinical Chemistry and Laboratory Medicine
|September 13, 2007
Summary
The apolipoprotein E (apoE) epsilon4 allele is linked to metabolic syndrome. This genotype is associated with higher triglycerides and lower HDL-C, increasing coronary heart disease risk.
Area of Science:
- Genetics
- Cardiovascular Disease
- Metabolic Disorders
Background:
- Metabolic syndrome is linked to lipid and lipoprotein metabolism disturbances.
- Apolipoprotein E (apoE) genotypes may influence metabolic syndrome and coronary heart disease (CHD) risk.
Purpose of the Study:
- To investigate the association between apoE genotypes and metabolic syndrome or CHD.
- To analyze lipid profiles and apoE genotype frequencies in different patient groups.
Main Methods:
- Study included 279 subjects: controls, metabolic syndrome patients, and obese CHD patients.
- Measurements included BMI, glucose, lipids (triglycerides, cholesterol, HDL-C, LDL-C).
- ApoE genotyping performed using PCR-RFLP on genomic DNA.
Main Results:
- Metabolic syndrome and CHD groups showed higher triglycerides and lower HDL-C than controls.
- ApoE epsilon4 allele frequency was higher in metabolic syndrome and CHD groups.
- The apoE4/3 genotype correlated with elevated triglycerides and reduced HDL-C.
Conclusions:
- ApoE genotypes are associated with metabolic syndrome and CHD risk factors.
- The epsilon4 allele of apoE is an independent risk factor for metabolic syndrome.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...